Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
OcuSciences
AddedFeb 18, 2024
UpdatedJun 18, 2026
OcuSciences

OcuSciences

Seed

OcuSciences: Innovating non-invasive ocular imaging devices for early detection and treatment of diabetes-related eye conditions.

HQ
Ann Arbor, MI, US
Founded
2008
Overview
Compare
Fundraising
Employees
Website

Founded with a mission to innovate non-invasive ocular imaging, OcuSciences is a medical diagnostic device company specializing in the early detection and monitoring of retinal metabolic dysfunction, particularly related to diabetes. The company’s flagship product, the OcuMet Beacon, utilizes the proprietary MitoPhor™ technology to provide rapid and automated assessments of ocular health. This technology aids ophthalmologists and optometrists in diagnosing and managing eye diseases efficiently.

OcuSciences has garnered attention for its cutting-edge approach to ocular health, attracting notable investors and affiliations within the medical and technological communities. The company's achievements include the successful development and deployment of the OcuMet Beacon, which has significantly impacted the early diagnosis and treatment of diabetes-related eye conditions. Through its innovative solutions, OcuSciences continues to enhance the quality of eye care and improve patient outcomes globally.

OcuSciences - Similar Companies

Ocutronics logo

Ocutronics

Oculir logo

Oculir

Bioxytech Retina logo

Bioxytech Retina

bioxytech.com

Retina Technologies logo

Retina Technologies

OcuDoc logo

OcuDoc

ocudocmobile.com

Optovue logo

Optovue

Oculogica logo

Oculogica

oculogica.com

Ocular Science logo

Ocular Science

ocularscience.com

OcuTerra Therapeutics logo

OcuTerra Therapeutics

ocuterratx.com

OcuMedic logo

OcuMedic

OcuCure Therapeutics logo

OcuCure Therapeutics

Opticent Health logo

Opticent Health

opticenthealth.com

Sight Sciences logo

Sight Sciences

sightsciences.com

Iscience Surgical logo

Iscience Surgical

EyeIC logo

EyeIC

OcuSciences - Quick Facts

Who are OcuSciences' competitors?

Companies similar to OcuSciences include Ocutronics, Oculir, Bioxytech Retina and Retina Technologies.

When was OcuSciences founded?

OcuSciences was founded in 2008.

Where is OcuSciences' headquarters located?

OcuSciences' headquarters is located in Ann Arbor, MI, US.

When was OcuSciences' last funding round?

OcuSciences' most recent funding round was for $900k (USD) in May 2009.

How much has OcuSciences raised to-date?

As of May 1, 2009, OcuSciences has raised a total of $900k (USD).

How many employees does OcuSciences have?

OcuSciences has 7 employees as of Feb 4, 2024.

OcuSciences - Classification

Industry
  • Hardware
Ownership
  • Private
Technology
  • Analytics
Geographic Exposure
  • Americas
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Medical Devices
Tags
  • Healthtech
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
SIC
  • 5000Wholesale Trade-durable Goods
  • 5040Professional And Commercial Equipment And Supplies
  • 5047Medical, Dental, And Hospital Equipment And Supplies
Show 7 more industry codes
NAICS
  • 330000Manufacturing
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 3900Miscellaneous Manufacturing Industries
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified